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[ ~  Ant loxklant  Effect of Can,'~lllol and Metoprolol In 
CongseUve Heart Failure 
M.L. Kukin, J, Kalman, RH. Charnoy, D,K, Levy, C, Buchholz-Varley, 
ON, O~mpo, C, Eng. Cardiova.~Jt~r tns~fute, Mount Sinai Sctx~ of 
Me~ne, NY. NY. USA 
Although the ant~x~ant pro!~ffias of CeC i le !  (C) I~ve beon measur~l m 
v~f~o in cell i~el~ttor~, l!loy have not been show~ m vn/o in has~ fa+t~re 
l~llents ItI~  ~ !vevmusly dereo~rated that lhlObe~ifur~C acid rea~iv~ 
=ubslan,~'e+ (T1BAR5), wl~:h are matkem of Iq~l pefoxldallon and omid~tive 
stress, am e/evatnd in CItF palltmts e~mpared to co~trols. TBAh~ ~tso 
ircreit~m wlth wOr~u~a~ ng NYHA class. To date, them have been no dire~ 
~r l s0~s  of C ar<l Metopmtol (M) in a CHF pupu!aben 
We randomly a~ig~4~d 56 palients (ol~n label) to M or C, Baseline 
evaluation inchJded eff~tv~ fra¢tio~ tEF). sVm~om score (SS), QOL lnck~x, 
6 mm walk. mVO~, ~nd TBARS as measured by ~rophofometry in the 
plasma,/~.blocke~ was g~adualty l~traled to a tart]el close of 25 mg b~d 150 mg 
b~l it wl :.85 kg) foe both C and M Backg~nd therapy consisted el A~ or 
ACE1195%). dlgoMin and ~Llrellcs. el lhe 56 pta (mean age 58) 43 ¢o~pleted 
6 months of long-term therapy. There ware 41 men and 15 women; etmlogy: 
~1 iselmm~, 30 ~liopathi¢, 5 valvular tt~th NYHA class !LqlI/tV: 11/39~. 
The entire group (C & M) showed s~gnd~=ant, parallel .~pmvements (p 
0.01) in EF 118 TO 22%), SS 110 3 to 7-5), CIOL (5~ to 37), walk (1152 to 
1247 feel), aP~l ,~/C~ {I~.~ to 120 ml,'kg,*m~n~, (by AN ~VA) with no between 
group ~ttemnce. 
TBARS conoentreben (ng,~ml) at weeks -2. 0 (baseline averaged) and 
Mo~tl~ 4 & 6 wdh C declined frem 5 L~ to 4 4 to 4 3 and wff'h M from 4 8 to 
4.6Io3.9. P =00002 for o~,rall change over t~me m both groups w;th no 
between group ~flerence. 
Thus, #-b~ockers demo,,~ste s~ndicant c~nical, bemo~'nam~c exercise, 
and antiomdant benefits over 6 months in th~ CHF pupulat~on with no dis- 
cernible c~fterence between C and M in any of the measured parameters. 
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~- -~-~ Effects of Carvedi lo l  o11 LV Function and / /  
Remodel ing in Patients W'dh Dilated 
Cardiomyopathy W.h  Persistent LV Dysfunction 
Oespite Optimal Conventional Therapy 
A. DI Lenarda. L Sahratore, D. Gregon, G. Smagra, G. Sal~0a~m'. 
F Lo~:jaro. E. Ben"~3b~h, S. Klugma~n, F. Camenm. Dept of Carc/~og~ 
Italy: ' Dept  of Internal Medicine e Geriatrics. Trieste. Italy 
Background" In order to analyze the adddn,,e ffect of carveddol (C) in ddated 
cardK)myopathy (IDC) with long htsto~' (61 • 51 munths) of symptomahc 
LV dysfunction despite chront¢ tadored motoprolol (M) and ACE ml'~l~tor 
treatment+ we enrolled 30 pts (peak VO2 - 25 ml~kg/mm and LVEF :u.40) 
to rendlomly continue open M (n = 16) (142 : 44 moJ~tay) or to cross to C 
(n = 14), uptltrated to the mammum tolerated ose (74 _~ 23 rag;day)+ fo~ 12 
months. 
Resu,'ls :
Banshee ~ 12 ~ths -ba~ehne 
M C p M C P 
NYHAI t -41  tg¢  1 16  = 1 = O I  =02 02 :06  
LVEF (%) 31 : 7 30 : 6 = 1 : 8 -7  -- 12 
LVEDV (mlJm2) 126 = 47 1~5 *. 33 = + 7 ~ ~ 8 ~ 28 § 
LVESV (ml:rn2) 91 ¢ 10 80 : 7 = -6  : 4 7 ; 5 = 
PeakVO2(mb1~g:m) 17 ++41 181 : 3 ' -1 - .2  1 :2  
Rest HR (bpm) 60 t 8 60 : 7 # 0 -* 1 - 1 : 1 " 
Leclend: EDV: end-d~astohc volume; ESV: end-systohc volume: HR heart rate. 1~) p = 
NS. I § )p -  010: ( ' ) :p -  005  
Conclusions: in pts with IDC and long history of symptomatic LV dys- 
function despite chronic optimal treatment, C. as compared to M, showed 
a significant additive effect on LV function and remodeling, although signifi- 
cantly decreased maximal exercise tolerance. 
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~ B e t a  in Chronic Heart Failure: Blockade Therapy 
Diastol ic Function and Mitral Regurgitation 
Improvement by Carvedilol 
S. Capomo[la. C. Opasich, G. Riccardi. O. Febo. R. Riccardi, F. Cobelli, 
L. Tavazzi. FACC: "Salvatore Maugeri" Foundation Institute of Medical Care 
and Researoh Montescano (Pavia). Italy 
Background. In patients with chronic heart failure the use of carvedilol ther- 
apy induces clinical and hemodynamic mprovements. However, data about 
the effects el Ca~tedllol on tt'k3 loft v0nteculM d~a~0hc funChon and m~lra! 
regurgitation am not well defined 
Ot~ct~v~ to ldentdy the chnlc~l, funohonat effe,~ of Calved~toL focusing 
the diastolic funchon and m=tral r0gurg~stton vanaf~ 
MethOd: tw~nlY.tour consecttlwe pstlents (52 • 8 yrs) with CHF (~ 
6%) due TO d+lated i~¢hem¢/r,~i~chem~C (9/15) C~omyo~tby •tmat¢~ 
with Cantedflol (mean ~e 44 ~ 30 rag). were matct',e~ to+ a control group to; 
ctlt~c.al (hmctK~l cla~s NYHA, CHF cluratK~) al~l ~ (C~r~a¢ 
m, de~ and pulmonary w~ pr~sum) ¢haracte~i=lK:s. We ~med_ two 
groups: GI: (24 pt~ Carvedilol group) and G2:(24 pt~; control group), CIm~ca! 
and eChocard~aph¢ vanabtee rn~ute~ m two grm~l~ at basel,s 
attol six mo~ths were cornpare~. 
0aselr~-~ (~ months 
ot G2 Gt G~ 
FC (bpm) R7 z 17 83 z 15 1~ z 9 ~ g4 ¢ 12 
LVEDV! (mLm2) 72 t Q 75 ~ 12 70 ~ 10 73 ~- 12 
LVE~VI tmL~2) 62 t t0  04 ¢ 14 57 • t l "  ~ ~ 17 
NYHA |t,tl fill 3~ 18,~J 41~'4  ~ ' t f l~  5!17F'2 
EF% 22 ~ ~ 23 t 7 ~t~ ~ 7 ~ 22 ': 
F~A I S ~ c '8  I t~¢ t t ?~09 f5~09 
nT  (m~ecl t32 ,~ 56 129 • 43 1~8 ± 76+" t3~5 ¢ 51 
MR (cm2.1 5 9 ~ 2 6 : 2 5 3 ~ 3 ~ fl 2 -* I fi 
( 'p  - 0 05 has VS 6 ~nthS  ~p ~ 0 05 G I  V~, G~ ) 
Conclusmns: After 6 months of frealment. Can/eddol l~s  a significant 
reducben of left ventncular end-systolic volume wrlh m~ement  at sys- 
tolic fun~.  These changes ware associated w~th restoratmn of d~astohc 
dysfunctmn and co.com~ant decrease of mltral regurg~at~m 
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I B41-1 I A New S'=ritegy for  the Su~ical  Treatment of  Aort ic 
Coarclatton Associated With Ventricular ~k, ptal 
Defect in Infants Using an Absorbable Pulmonary 
Artery Band 
D. Bonnet, 0. TamJster, J Patkai, D. Sr(h, P Acar, J Kacha;mr, PR Vouhe 
Ho~mt Necker-EntarCs Malao~es. Pans. France 
Bac~grounCt OeosTon makm;) for the surgical management of aortic coarcta- 
ben (CoAl assooated w~h ventncular septal defect (VSD) may be ddfmult m 
:c#',a:'ds. The altemalnre is single stage repair versus CoA repazr with banding 
of the pulmenary artery AS a large profxy~on of the VSD assocraled with 
CoA are prone to close spontaneously, we propose a new uifai~gy using 
CoA repair ~th absorbable pulmonary banding, 
Methods: Nine mtanP~ [mean werghf 3050 ± 800 g, range 143~ g] 
undem~nt a CoA repair with a polyo'ioxanone banding through a posterolat- 
eml approach at a mean age of 22 days [8--41 days). Fwe had a trabecular 
VSD and 4 a penmembranous VSD [4-7 mini wtrn ~osystamm pulmonary 
hypedenF,~on The pulmmtary bend was t;ghfened untd the systolic pulmonary 
pressure felt below 50% of the aortic pressure. 
Results: There was no hospital death. The resorptTon of the pulmonary 
b:trYJ wa.~ cu;~pleto after 4.5 months in all patients [3-5.5 months]. The VSD 
closed completely m 2 infants and pa~alty in 6 in whom the pulmonary artery 
pressure was normal wTthout ev~erme for significant left-to.right shunt. One 
patient wsth a large muscular VSD underwent surgical closure of his defect 
after 4 months. Finally. a subsequent open heat surgery could be avoided in 
89% (8J9) patients 
Conclusion: Prowded the VSD belongs to types charactenzed by a high 
incidence of spontaneous closure, thrs effectwe pol icy may n~uco the num- 
ber of sur~cal procedures per infant, m-has.tel mortality and morbidity rates 
It should be proposed as an alternatrve m the panel of surgical ogb0ns in this 
disease. 
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~4"~ Minimally invasive Approach for ASD Repair 
A.C. Galloway. R.V. Anderson. J S. Miller. E.A. Grossi. F.G Baumann. 
J. Delianides. R. Verma. M. Adman. S.B. Calvin+ New York University 
Medical Center, New York. NY. USA 
Background: A m n really invaswe n9,~,, thoracotomy ,he, start, when feast- 
